



(51) International Patent Classification:

C07D 413/14 (2006.01) *C07D 417/14* (2006.01)
A61K 31/4184 (2006.01) *C07D 487/04* (2006.01)
A61K 31/437 (2006.01) *C07D 487/08* (2006.01)
C07F 9/50 (2006.01) *C07D 487/10* (2006.01)
C07D 403/04 (2006.01) *A61P 35/00* (2006.01)
C07D 403/14 (2006.01)

(21) International Application Number:

PCT/US2014/069469

(22) International Filing Date:

10 December 2014 (10.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/914,128 10 December 2013 (10.12.2013) US
 62/040,750 22 August 2014 (22.08.2014) US

(71) Applicant: GENZYME CORPORATION [US/US]; 500
Kendall Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors; and

(71) Applicants : KANE, John L. [US/US]; c/o Sanofi, 55
 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New
 Jersey 08807 (US). MATTHEWS, Gloria [US/US]; c/o
 Sanofi, 55 Corporate Drive, Mail Code: 55A-505A,
 Bridgewater, New Jersey 08807 (US). METZ, Markus
 [CA/US]; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-
 505A, Bridgewater, New Jersey 08807 (US). KOTHE,
 Michael [DE/US]; c/o Sanofi, 55 Corporate Drive, Mail
 Code: 55A-505A, Bridgewater, New Jersey 08807 (US).
 LIU, Jinyu [CN/US]; c/o Sanofi, 55 Corporate Drive, Mail
 Code: 55A-505A, Bridgewater, New Jersey 08807 (US).
 SCHOLTE, Andrew [CA/US]; c/o Sanofi, 55 Corporate
 Drive, Mail Code: 55A-505A, Bridgewater, New Jersey
 08807 (US).

(74) Agents: ORT, Ronald G. et al.; Sanofi U.S., 55 Corporate
 Drive, Mail Code: 55A - 505A, Bridgewater, New Jersey
 08807 (US).

(81) Designated States (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
 kind of regional protection available*): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the
 earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with amended claims (Art. 19(1))*

(54) Title: TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS

(57) Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

